SRPT
Sarepta Therapeutics Inc
18.70$
+1.5%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +19.6% | +4.2% | -12.2% | +28.7% | +40.9% | +13.1% | -18.0% | -34.6% | +10.9% | +65.0% | -45.1% | – | |
| – | +19.3% | +14.4% | -11.9% | +105.8% | +44.3% | +4.0% | +10.9% | -1.2% | +164.4% | -70.1% | +25.2% | – | |
| – | +19.6% | +2.9% | -12.3% | +17.9% | +40.1% | +15.4% | -24.5% | -45.8% | -82.2% | +1,282.5% | -58.8% | – | |
| – | +0.6% | +2.5% | -10.3% | +24.9% | -10.9% | +286.8% | -73.6% | +7.1% | +48.6% | -52.7% | -40.7% | – | |
| – | +8.9% | -3.6% | +9.3% | -7.6% | +27.8% | -18.5% | +3.2% | -33.4% | +39.6% | -15.1% | -1.2% | – | |
| – | +3.9% | +0.0% | -2.7% | +10.7% | +3.2% | +149.1% | -62.2% | +2.6% | +29.5% | -44.5% | -5.7% | – | |
| – | – | +41.7% | -102.0% | – | +628.4% | -285.8% | – | -189.5% | – | – | -96.3% | – | |
| – | +0.1% | -20.4% | +16.0% | +1.8% | -9.0% | +0.6% | +16.1% | +44.7% | +0.0% | +187.0% | -0.9% | – | |
| – | – | +2.7% | -67.2% | +150.5% | +405.0% | -323.3% | – | -226.3% | – | – | -100.5% | – | |
| – | -168.1% | – | +33.6% | -94.4% | +3,113.7% | +404.1% | -167.6% | – | – | +168.4% | -74.3% | – | |
| – | – | -20.9% | -82.1% | +420.3% | +373.2% | -381.4% | – | -191.4% | – | – | -101.5% | – | |
| – | – | -4.6% | -50.1% | +79.6% | +283.1% | -297.7% | – | -199.0% | – | – | -92.0% | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.